Skip to main content
$5.90 -$0.01 (-0.2%)

04:00 PM EST on 01/27/23

Veru, Inc. (NASDAQ:VERU)

CAPS Rating: No stars

Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers.

Current Price $5.90 Mkt Cap $476.5M
Open $5.88 P/E Ratio 0.00
Prev. Close $5.90 Div. (Yield) $0.00 (0.0%)
Daily Range $5.81 - $6.09 Volume 1,837,722
52-Wk Range $4.34 - $24.55 Avg. Daily Vol. 2,380,901

Caps

How do you think NASDAQ:VERU will perform against the market?

Add Stock to CAPS Watchlist

All Players

5 Outperform
1 Underperform
 

All-Star Players

0 Outperform
0 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:VERU Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

lemiwinx (49.42)
Submitted July 14, 2022

Their sabizabulin drug has been submitted for emergency authorized use to the FDA. The drug was successful in reducing deaths by over 50% in severe COVID patients. If successful, this drug will save many lives and generate plenty of revenue to… More

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

NASDAQ:VERU Summary

  • Sector:
  • Industry:
  • Tags:

Fools bullish on NASDAQ:VERU are also bullish on:

Recent Community Commentary

Read the most recent pitches from players about VERU.

Recs

0
Member Avatar alvinpall (54.12) Submitted: 10/13/2022 8:10:48 PM : Outperform Start Price: $11.48 NASDAQ:VERU Score: -59.07

Veru has a unique situation. a drug that stops death from covid 55% of the time or more. It also stops any variant.by dismantling the cytokine cloud so covid can not get to your lungs. They have been used for emergency situations for some time and they should easily pass the FDA requirements. they also have 2 or 3 drugs in the pipeline for prostate cancer and breast cancer. They have 2 more drugs which have been funding their research so they make some money which isn't used as for instance a p/e ratio. Look for higher prices on this company and stock.

Recs

1
Member Avatar lemiwinx (49.42) Submitted: 7/14/2022 1:39:27 PM : Outperform Start Price: $15.41 NASDAQ:VERU Score: -70.79

Their sabizabulin drug has been submitted for emergency authorized use to the FDA. The drug was successful in reducing deaths by over 50% in severe COVID patients. If successful, this drug will save many lives and generate plenty of revenue to complete their research/trials of their oncology treatments which also uses some parts of sabizabulin.

Leaderboard

Find the members with the highest scoring picks in VERU.

Score Leader

Tangoko

Tangoko (< 20) Score: +66.85

The Score Leader is the player with the highest score across all their picks in VERU.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
TMFdjagielski 53.10 9/23/2022 Underperform 1Y $10.44 -43.41% +9.93% +53.34 0 Comment
alvinpall 54.12 10/14/2022 Outperform 3Y $11.48 -48.54% +10.53% -59.07 1 Comment
TMFGBudwell < 20 8/25/2022 Outperform 5Y $18.14 -67.43% -1.90% -65.54 0 Comment
conliskjr < 20 7/12/2022 Outperform 3Y $14.75 -59.96% +6.18% -66.14 0 Comment
lemiwinx 49.42 7/14/2022 Outperform 5Y $15.41 -61.66% +9.12% -70.79 1 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. naylorj 64.94 7/15/2022 Outperform 1Y $17.47 -66.18% +6.00% -72.17 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for VERU.